Issue Date: May 14, 2007
Lonza Plans Output of Conjugate Drugs
Custom manufacturer Lonza plans to start large-scale production of antibody-drug conjugates, a targeted therapy in which an antibody is coupled to a highly active chemical substance. Lonza says it will open a plant in Visp, Switzerland, by 2008 with capacity for more than 100 kg of the conjugates annually. Uwe Böhlke, Lonza's head of exclusive synthesis, says the investment "is a perfect match with Lonza's capabilities and technologies in both chemical and mammalian antibody manufacture."
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society